泰格捷通是泰格医药(股票代码:300347.SZ/3347.HK)全资子公司，成立 于2000年，是中国领先的医疗器械(含体外诊断产品)法规事务及临床研 究CRO服务提供商，覆盖医疗器械各领域全生命周期。在过去的20年中， 我们与来自30多个国家的1700多家医疗器械研发及生产企业建立了长 期的合作关系。以我们专业的服务能力为客户降低注册风险、缩短项目 周期、节约研发经费，推进产品市场化进程。
Tigermed-Jyton , a wholly-owned subsidiary of Tigermed Group ( Stock code : 300347.SZ/3347.HK ) , was established in 2000 , and is a leading CRO service provider in China for regulatory affairs and clinical research ofmedical debices (including in vitro diagnostic products) , with service covering the whole life cycle of all fields of medical devices. In the past 20years,we have established long-trem cooperative relations with more than1,700 medical device R&D and manufacture enterprises from more than 30countries. With our professional service capability, we can reduce registration risk, shorten project timeline, save R&D funds and accelerate the process of product marketization.